- Walgreens partners with United Nations Foundation's Shot@Life campaign
- At least 23,000 die from antibiotic-resistant infections each year, CDC finds
- Study: Pharmacist intervention improves shingles vaccine rate
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Chickenpox vaccine does not appear to increase incidence of shingles, study finds
RALEIGH, N.C. — Napo Pharmaceuticals has filed a lawsuit against Salix Pharmaceuticals, alleging that the latter breached commitments under an agreement to develop and commercialize a proprietary gastrointestinal compound.
Salix said that Napo's claims over its collaboration agreement concerning the development of crofelemer are without merit, adding that the drug maker plans to continue with the development and commercialization of crofelemer, in accordance with its past guidance and the terms of its collaboration agreement with Napo.
Crofelemer is Napo's lead drug candidate, according to the company's website, and is under development for gastrointestinal indications, including chronic diarrhea in patients living with HIV/AIDS.